Combination therapy of paclitaxel and UVB1 in HNSCC and TNBC cells

IBARRA A.; CLEMENTE V.; SCHWEITZER K.; COLO G.P.; ALONSO E.N.; FERMENTO M.E.; FACCHINETTI M.M.; FERRONATO M.J.; CURINO A. C.

Mar del Plata

Congreso; LXVIII Reunión Anual de la Sociedad Argentina de Investigación clínica (SAIC).; 2023

Sociedad Argentina de Investigación clínica (SAIC).

Head and Neck Squamous Cell Carcinoma (HNSCC) and Triple Negative BreastCancer (TNBC) are heterogeneous and aggressive tumors with high mortality anddifficult clinical management. Conventional chemotherapy remains as the main clinicalmanagement with the concomitant undesirable side effects for patients and timelimited positive responses. Further research is needed to find novel therapeuticstrategies that prolong the patient survival and ensure a better quality of life. The aimof the present study was to evaluate the antitumor potential of the combination of theconventional chemotherapeutic agent Paclitaxel (PTX) with the non-hypercalcemicCalcitriol analog UVB1 in HNSCC and TNBC cells. Cell viability was evaluated bycrystal violet assays in human HN13 and HN12 HNSCC and murine 4T1 TNBC celllines treated with vehicle, UVB1, PTX or combination of drugs. The results show thatUVB1 (1μM) with low concentrations of PTX displayed a greater reduction in viabilitywith respect to control and monotherapies in all cell lines tested (120h of treatment,p